logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Renal Pharmacotherapy Second Larry K Golightly Isaac Teitelbaum

  • SKU: BELL-34966626
Renal Pharmacotherapy Second Larry K Golightly Isaac Teitelbaum
$ 31.00 $ 45.00 (-31%)

4.3

18 reviews

Renal Pharmacotherapy Second Larry K Golightly Isaac Teitelbaum instant download after payment.

Publisher: Springer Nature
File Extension: PDF
File size: 5.4 MB
Pages: 827
Author: Larry K. Golightly, Isaac Teitelbaum, Bonita A. Simendinger, Tyree H. Kiser, Gerard R. Barber, Nancy M. Stolpman
ISBN: 9783030586508, 3030586502
Language: English
Year: 2021
Edition: Second

Product desciption

Renal Pharmacotherapy Second Larry K Golightly Isaac Teitelbaum by Larry K. Golightly, Isaac Teitelbaum, Bonita A. Simendinger, Tyree H. Kiser, Gerard R. Barber, Nancy M. Stolpman 9783030586508, 3030586502 instant download after payment.

To promote effectiveness and minimize possible toxicity, the dosage of certain medications must be adjusted in persons with compromised kidney function. Failure to enjoin appropriate dosage adjustments in patients with abnormal or rapidly changing kidney function continues to lead to reports of drug toxicity involving a broad array of renally eliminated medications. This updated edition captures nearly 200 new drugs that have been approved by the FDA since the initial publication of Renal Pharmacotherapy. It also covers new evidence that has emerged regarding the need to adjust dosage of certain older medications that are eliminated by the kidneys. Additionally, it presents new data that are being continuously derived in the areas of patient-specific dose individualization for drugs of all types. Comprehensive, convenient, and evidence-based, this reference closes several identified knowledge gaps and will continue to be the leading collection of dosage recommendations for patients with compromised kidney function.

Related Products